Frankfurt
13.03.26 | 21:47
0,103 Euro
+6,19 % +0,006
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | SkinBioTherapeutics adds interim CEO Rachel Parsonage to board | 2 | Alliance News | ||
| Mo | SkinBioTherapeutics - Appointment of the Interim CEO to the Board | - | RNS | ||
| SKINBIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.03. | AIM Market Roundup: IQE, System1, SkinBioTherapeutics | 2 | The Armchair Trader | ||
| 02.03. | SkinBioTherapeutics appoints interim CEO as investigation continues | 2 | Alliance News | ||
| 02.03. | SkinBioTherapeutics - Appointment of Interim CEO | 1 | RNS | ||
| 20.02. | IN BRIEF: SkinBioTherapeutics board member to oversee external probe | 1 | Alliance News | ||
| 20.02. | Skinbiotherapeutics brings in new audit chair, launches forensic review | 1 | Sharecast | ||
| 20.02. | UK Stock Market News: Anglo American, SEGRO, SkinBioTherapeutics | 4 | The Armchair Trader | ||
| 20.02. | SkinBioTherapeutics - Independent Investigation Appointment | - | RNS | ||
| 16.02. | ProBiotix says shares hit by "mistaken assumptions" of link to SkinBio | 2 | Alliance News | ||
| 16.02. | SkinBioTherapeutics forced to reverse royalty income statement | 1 | The Armchair Trader | ||
| 16.02. | SkinBioTherapeutics says ex-CEO "misrepresented material information" | 2 | Alliance News | ||
| 16.02. | SkinBioTherapeutics dives on warning of major FY25 revenue restatement | 1 | Sharecast | ||
| 16.02. | SkinBioTherapeutics storniert Lizenzeinnahmen von 0,77 Mio. Pfund nach Ermittlungen gegen Ex-CEO | 1 | Investing.com Deutsch | ||
| 16.02. | SkinBioTherapeutics to reverse £0.77m in royalty income amid CEO probe | 3 | Investing.com | ||
| 16.02. | SkinBioTherapeutics - Update on Board Investigation | 3 | RNS | ||
| 13.02. | SkinBioTherapeutics CEO resigns | 1 | Sharecast | ||
| 13.02. | AIM WINNERS & LOSERS: SkinBioTherapeutics sinks as CEO suspended | 4 | Alliance News | ||
| 13.02. | IN BRIEF: SkinBioTherapeutics CEO Ashman resigns amid probe of conduct | 2 | Alliance News | ||
| 13.02. | SkinBio Therapeutics CEO resigns | 2 | Sharecast |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MAAT PHARMA | 6,820 | +0,59 % | MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management | Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft-versus-Host Disease (aGvHD) with gastrointestinal... ► Artikel lesen | |
| QIAGEN | 36,035 | +1,84 % | Aktuelle Aktien-Empfehlungen: Daimler Truck, Fresenius, Qiagen & Co. | Die Analystenhäuser haben zum Wochenschluss eine Reihe neuer Kaufempfehlungen für internationale und deutsche Aktien veröffentlicht. Mehrere Research-Institute sehen in unterschiedlichen Branchen weiterhin... ► Artikel lesen | |
| ERASCA | 13,620 | -7,09 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,190 | -2,96 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results | - The FDA assigned a PDUFA target action date of December 22, 2026 - - The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction... ► Artikel lesen | |
| BIONTECH | 79,95 | +0,44 % | Biontech-Gründer verlassen das Unternehmen - das planen sie jetzt | Sahin und Türeci waren die Gesichter von Biontech - dem Unternehmen, das mit dem Partner Pfizer die erste Zulassung für einen Corona-Impfstoff bekam. Nun wagt das Forscher-Ehepaar noch einmal Neues.... ► Artikel lesen | |
| EVOTEC | 4,175 | -3,02 % | Evotec-Aktie: Dieser Tag entscheidet | Die Evotec-Aktie hat heute einen wichtigen Tag vor sich. Der Aktienkurs muss unbedingt die Kursmarke bei 5,40 Euro verteidigen, ansonsten wird ein neues Kursziel aktiviert werden, das dann sinkende... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 21,310 | +0,12 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 2,085 | +96,70 % | bioAffinity Technologies GAAP EPS of -$8.66, revenue of $6.2M | ||
| COGENT BIOSCIENCES | 33,950 | -4,07 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| CG ONCOLOGY | 64,35 | +2,22 % | CG Oncology stock rating reiterated at Buy by Truist Securities | ||
| PRAXIS PRECISION MEDICINES | 294,05 | -2,99 % | BTIG reiterates Buy on Praxis Precision Medicines stock at $843 | ||
| LEXEO THERAPEUTICS | 6,660 | +0,45 % | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants... ► Artikel lesen | |
| ARCELLX | 114,36 | +0,04 % | Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? | ||
| TECTONIC THERAPEUTIC | 33,310 | -2,26 % | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")... ► Artikel lesen | |
| NUVALENT | 97,96 | -0,04 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen |
SKINBIOTHERAPEUTICS PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +6,19 % bei einem Aktienkurs von 0,103 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SKINBIOTHERAPEUTICS PLC finden Sie auf Wallstreet Online.